|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiofrequency ablation for early oesophageal squamous neoplasia:Outcomes form United Kingdom registry显示文摘AIM:To report outcomes on patients undergoing radiofrequency ablation(RFA)for early oesophageal squamous neoplasia from a National Registry.METHODS:A Prospective cohort study from 8 tertiary referral centres in the United Kingdom.Patients with squamous high grade dysplasia(HGD)and early squamous cell carcinoma(ESCC)confined to the mucosa were treated.Visible lesions were removed by endoscopic mucosal resection(EMR)before RFA.Following initial RFA treatment,patients were followed up 3monthly.Residual flat dysplasia was treated with RFA until complete reversal dysplasia(CR-D)was achieved or progression to invasive Squamous cell cancer defined as infiltration into the submucosa layer or beyond.The main outcome measures were CR-D at 12 mo from start of treatment,long term durability,progression to cancer and adverse events.RESULTS:Twenty patients with squamous HGD/ESCC completed treatment protocol.Five patients(25%)had EMR before starting RFA treatment.CR-D was 50%at12 mo with a median of 1 RFA treatment,mean 1.5(range 1-3).Two further patients achieved CR-D with repeat RFA after this time.Eighty per cent with CR-D remain dysplasia free at latest biopsy,with median follow up 24 mo(IQR 17-54).Six of 20 patients(30%)progressed to invasive cancer at 1 year.Four patients(20%)required endoscopic dilatations for symptomatic structuring after treatment.Two of these patients have required serial dilatations thereafter for symptomatic dysphagia with a median of 4 dilatations per patient.The other 2 patients required only a single dilatation to achieve an adequate symptomatic response.One patient developed cancer during follow up after end of treatment protocol.CONCLUSION:The role of RFA in these patients re-mains unclear.In our series 50%patients responded at12 mo.These figures are lower than limited published data. | Rehan J Haidry Mohammed A Butt Jason Dunn Matthew Banks Abhinav Gupta Howard Smart Pradeep Bhandari Lesley Ann Smith Robert Willert Grant Fullarton Morris John Massimo Di Pietro Ian Penman Marco Novelli Laurence B Lovat | 2013 | World Journal of Gastroenterology2013，19，36： | 7 |
| 2 | 中国城市生活垃圾处置状况及治理研究显示文摘中国城市生活垃圾存量高、增速快,生活垃圾治理要真正实现“减量化、无害化、资源化”的目标,面临着垃圾分类不规范、情境性强、区域间发展不平衡、公众参与效率低、“运动式”治理等困境。基于全国城市生活垃圾处置历年数据分析,2005—2019年全国城市生活垃圾清运量呈逐步上升趋势,区域间垃圾清运量、处理方式与处理能力存在明显差异。政府包揽型垃圾治理模式导致政府负担重,治理效率低等问题,构建政府、公众、市场、专业机构、媒体和非营利组织等多元主体参与的治理体系,是破解我国城市生活垃圾治理困境的必由之路。 | 龚文娟 赵曌 BUTT A W | 2022 | 海南大学学报(人文社会科学版)2022，40，3： | 6 |
| 3 | Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes显示文摘The hepatitis C virus(HCV) is one of the most common causes of chronic liver disease and the leading indication for liver transplantation worldwide. Every aspect of the HCV life cycle is closely tied to human lipid metabolism. The virus circulates as a lipid-rich particle, utilizing lipoprotein cell receptors to gain entry into the hepatocyte. It has also been shown to upregulate lipid biosynthesis and impair lipid degradation, resulting in significant intracellular lipid accumulation and circulating hypocholesterolemia. Patients with chronic hepatitis C(CHC) are at increased risk of hepatic steatosis, fibrosis, and cardiovascular disease including accelerated atherosclerosis. HMG Co A Reductase inhibitors, or statins, have been shown to play an important role in the modulation of hepatic steatosis and fibrosis, and recent attention has focused upon their potential therapeutic role in CHC. This article reviews the hepatitis C viral life cycle as it impacts host lipoproteins and lipid metabolism. It then describes the pathogenesis of HCV-related hepatic steatosis, hypocholesterolemia and atherosclerosis, and finally describes the promising anti-viral and anti-fibrotic effects of statins, for the treatment of CHC. | Tracey G Simon Adeel A Butt | 2015 | World Journal of Gastroenterology2015，21，27： | 5 |
| 4 | Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage显示文摘AIM: To evaluate pegylated interferon alpha2a (PegIFN- α2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate. METHODS: A total of 73 na?ve patients (61 with history of bilharziasis) with compensated chronic HCV genotype 4 were enrolled into: group A (38 patients) who received 180 mg PegIFN-alpha2a subcutaneously once weekly for a year and group B (35 patients) received IFN alpha-2a 3 MU 3 times weekly. Ribavirin was added to each regimen at a dose of 1200 mg. Patients were followed for 72 wk and sustained response was assessed. RESULTS: Significant improvement in both end of treatment response (ETR) (P < 0.002) and sustained response (SR) (P < 0.05) was noted with pegylated interferon, where ETR was achieved in 29 (76.3%) and 14 patients (40%) in both groups respectively, and 25 patients in group A (65.8%) and 9 (25.7%) in group B could retain negative viraemia by the end of follow up period. Sustained virological response (SVR) showed a significant negative correlation with age and positive correlation with pretreatment inflammation in patients receiving PegIFN. Viral clearance after 3 mo of therapy was associated with high incidence of ETR and SR (P < 0.001), but without significant difference between both forms of interferon. Significant improvement in response was achieved in patients with high grade fibrosis (grade 3 and 4) with PegIFN-α2a, where SR was seen in 5 out of 13 patients in group A, but none in group B. There was no significant difference in response betweenbilharzial and non-bilharzial patients in both groups. In terms of safety and tolerability, neutropenia was the predominant side effect; both drugs were comparable. CONCLUSION: PegIFN-α2a combined with ribavirin results in improvement in sustained response in HCV genotype 4, irrespective of history of bilharzial infestation. | MF Derbala SR Al Kaabi NZ El Dweik F Pasic MT Butt R Yakoob A Al-Marri AM Amer N Morad A Bener | 2006 | World Journal of Gastroenterology2006，12，35： | 3 |
| 5 | Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia,Canada显示文摘AIM To describe the characteristics of people diagnosed with acute and chronic hepatitis B virus(HBV) infection in British Columbia(BC).METHODS We used data from the BC Hepatitis Testers Cohort(BCHTC),which includes all individuals tested for hepatitis C virus(HCV) or human immunodeficiency virus(HIV) or those diagnosed with HBV or active tuberculosis in BC since 1990.These data were integrated with prescription drug,medical visit,hospitalization and mortality data.HBV cases were classified as acute or chronic according to provincial guidelines.We compared characteristics of individuals by HBV infection group(acute,chronic and negative).Factors associated with acute or chronic HBV infection were assessed with multinomial logistic regression models in comparison to the HBV negative group.RESULTS46498 of the 1058056 eligible BC-HTC participants were diagnosed with HBV infection.4.3% of HBV positive individuals were diagnosed with acute HBV infections while 95.7% had chronic infections.Problematic alcohol use,injection drug use,and HIV or HCV co-infection were more common among individuals diagnosed with acute HBV compared to those with chronic infections and HBV negative individuals.In multivariable multinomial logistic regression models,we observed significant associations between acute or chronic HBV diagnosis and being male,age at HBV diagnosis or birth cohort,South and East Asian ethnicity,HCV or HIV infection,and injection drug use.The odds of acute HBV decreased with increasing age among people who inject drugs,while the opposite was true for chronic HBV.Persons with acute HBV were predominantly White(78%) while those with chronic HBV were mostly East Asian(60%).Relative to Whites,East Asians had 12 times greater odds of being diagnosed with chronic HBV infection.These odds increased with increasing socioeconomic deprivation.CONCLUSION Differences in the profiles of people diagnosed with acute and chronic HBV infection necessitate differentiated screening,prevention,care and treatment programs. | Mawuena Binka Zahid A Butt Stanley Wong Mei Chong Jane A Buxton Nuria Chapinal Amanda Yu Maria Alvarez Maryam Darvishian Jason Wong Gina McGowan Mikhail Torban Mark Gilbert Mark Tyndall Mel Krajden Naveed Z Janjua | 2018 | World Journal of Gastroenterology2018，24，11： | 3 |
| 6 | Randomized phase Ⅱ B trial of BLP25 liposome vaccine in stage Ⅲ B and Ⅳ non-small cell lung cancer显示文摘 | Butts C Murray N Maksymiuk A | 2006 | J Clin Oncol2006，23，27： | 1 |
| 7 | Thermal stability of retained austenite in TRIP steels studied by synchrotron X-ray diffraction during cooling显示文摘 | Van Dijk N H Butt A M | 2005 | Acta Materialia2005，53，： | 1 |
| 8 | A qualitative study of qual- ity of life after stroke: The importance of social relationships显示文摘 | Lynch EB Butt Z Heinemann A | 2008 | J Rehabil Med2008，40，7： | 1 |
| 9 | Translational bioinformatics: linking know-ledge across biological and clinicalrealm s显示文摘 | Sarkar IN Butte AJ Lussier Y A | 2011 | J Am Med Inform A ssoc2011，18，4： | 1 |
| 10 | Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study 显示文摘 | Kumarasamy KK Toleman MA Walsh TR Bagaria J Butt F Balakrishnan R Chaudhary U Doumith M Giske CG Irfan S Krishnan P Kumar AV Maharjan S Mushtaq S Noorie T Paterson DL Pearson A Perry C Pike R Rao B Ray U Sarma JB Sharma M Sheridan E Thirunarayan MA Turton J Upadhyay S Warner M Welfare W Livermore DM Woodford N | 2010 | Lancet Infect Dis2010，10，9： | 1 |
| 11 | Clinical trial of post- chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer显示文摘 | Yee D Butts C Reiman A | 2012 | Radiother Oncol2012，102，2： | 1 |
| 12 | Exploiting drug-disease relationships for computational drug repositioning显示文摘 | Dudley J T Deshpande T Butte A J | 2011 | Briefings in bioinformatics2011，，： | 1 |
| 13 | Photochemical degradation of nitrated musk compounds 显示文摘 | BUTTE W SCHMIDT S SCHMIDT A | 1999 | Chemosphere1999，38，6： | 1 |
| 14 | Cells Expressing the NG2 Antigen Contact Nodes of Ranvier in Adult CNS White Matter 显示文摘 | BUTT AM DUNCAN A HORNBY MF | 1999 | Gila(S0894-4191)1999，26，1： | 1 |
| 15 | Are there any risks in using entomopathogenic fungi for pest control, with particular reference to the bioactive metabolites of Metarhizium, Tolypocladium and Beauveria species ? 显示文摘 | Strasser H Vey A Butt T M | 2000 | Biocontrol Science and Technology2000，10，6： | 1 |
| 16 | Strategies ofmaking TiO2 and ZnO visible light active显示文摘 | Rehman S Ullah R Butt A M | 2009 | J HazardMater2009，170，23： | 1 |
| 17 | Prevalence of anxiety and depression in osteoarthritis: use of the Hospital Anxiety and Depression Scale as a screening tool显示文摘 | Axford J Butt A Heron C | 2010 | Clin Rheumatol2010，29，11： | 1 |
| 18 | Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines 显示文摘 | Butt A Q Mills K | 2014 | Oneogene2014，33，38： | 1 |
| 19 | Corporate governance and earnings management an empirical evidence form Pakistani listed companies 显示文摘 | Shah S Butt S A Hasan A | 2009 | European Journal of Scientific Research2009，26，4： | 1 |
| 20 | Pharmacologic resuscitation:cell protective mechanisms of histone deacetylase inhibition in lethal hemorrhagic shock显示文摘 | Butt M U Sailhamer E A Li Y | | 0，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员